Traws Pharma Appoints BDO USA as New Auditor
Ticker: TRAW · Form: 8-K · Filed: Jul 19, 2024 · CIK: 1130598
| Field | Detail |
|---|---|
| Company | Traws Pharma, Inc. (TRAW) |
| Form Type | 8-K |
| Filed Date | Jul 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
Traws Pharma ditches old accountants for BDO USA, effective immediately.
AI Summary
On July 16, 2024, Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) announced a change in its certifying accountant. The company has appointed BDO USA, LLP as its new independent registered public accounting firm, replacing WithumSmith+Brown, PC. This change is effective immediately.
Why It Matters
A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, which investors will monitor.
Risk Assessment
Risk Level: low — The filing solely reports a change in the company's independent auditor, which is a routine administrative event.
Key Players & Entities
- Traws Pharma, Inc. (company) — Registrant
- BDO USA, LLP (company) — New Certifying Accountant
- WithumSmith+Brown, PC (company) — Former Certifying Accountant
- July 16, 2024 (date) — Date of earliest event reported
FAQ
When was the change in Traws Pharma's certifying accountant effective?
The change in Traws Pharma's certifying accountant was effective immediately as of July 16, 2024.
Who is Traws Pharma's new independent registered public accounting firm?
Traws Pharma, Inc. has appointed BDO USA, LLP as its new independent registered public accounting firm.
Who was Traws Pharma's previous certifying accountant?
Traws Pharma, Inc.'s previous certifying accountant was WithumSmith+Brown, PC.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is July 16, 2024.
What was Traws Pharma, Inc.'s former name?
Traws Pharma, Inc.'s former name was Onconova Therapeutics, Inc.
Filing Stats: 576 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-07-19 16:01:32
Filing Documents
- tm2419807d1_8k.htm (8-K) — 26KB
- tm2419807d1_ex16-1.htm (EX-16.1) — 3KB
- 0001104659-24-081155.txt ( ) — 197KB
- tmb-20240716.xsd (EX-101.SCH) — 3KB
- tmb-20240716_lab.xml (EX-101.LAB) — 33KB
- tmb-20240716_pre.xml (EX-101.PRE) — 22KB
- tm2419807d1_8k_htm.xml (XML) — 4KB
01
Item 4.01 Changes in Registrant's Certifying Accountant. On July 16, 2024, the Audit Committee of the Board of Directors of Traws Pharma, Inc. (the "Company") engaged KPMG LLP ("KPMG") as the Company's new independent registered public accounting firm for the year ended December 31, 2024. During the fiscal years ended December 31, 2023 and December 31, 2022, and the interim period through July 16, 2024, the Company did not consult with KPMG regarding: (i) the application of accounting principles to a specified transaction, either proposed or completed, or the type of audit opinion that might be rendered on the Company's financial statements, and neither a written report nor oral advice was provided to the Company that KPMG concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a "disagreement" (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a "reportable event" (as that term is defined in Item 304(a)(1)(v) of Regulation S-K). The Company has requested Ernst and Young LLP to furnish it a letter addressed to the U.S Securities and Exchange Commission ("SEC") stating whether it agrees with the above statements. A copy of that letter, dated July 19, 2024 is filed as Exhibit 16.1 to this Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Exhibit 16.1 Letter from Ernst and Young LLP 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: July 19, 2024 TRAWS PHARMA, INC. By: /s/ MARK GUERIN Name: Mark Guerin Title: Chief Financial Officer 2